Italia markets open in 6 hours 9 minutes

Grifols, S.A. (GRF.MC)

MCE - MCE Prezzo differito. Valuta in EUR.
Aggiungi a portafoglio
20,50-0,13 (-0,63%)
Alla chiusura: 5:35PM CEST
Schermo intero
Chiusura precedente20,63
Aperto20,64
Denaro20,52 x 0
Lettera20,54 x 0
Min-Max giorno20,38 - 20,81
Intervallo di 52 settimane19,18 - 26,94
Volume745.286
Media Volume816.898
Capitalizzazione11,949B
Beta (5 anni mensile)0,10
Rapporto PE (ttm)21,16
EPS (ttm)0,97
Prossima data utili03 nov 2021 - 08 nov 2021
Rendimento e dividendo (forward)0,36 (1,78%)
Data ex dividendo03 giu 2021
Stima target 1A27,00
  • GlobeNewswire

    GigaGen Doses First Patient in Phase 1 Trial of Recombinant Hyperimmune Polyclonal Antibody GIGA-2050 for COVID-19

    First-in-human study evaluating recombinant hyperimmunes SOUTH SAN FRANCISCO, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today the first patient has been dosed in its Phase 1 clinical trial of GIGA-2050, the company’s recombinant hyperimmune polyclonal antibody drug designed to provide passive immunity